Dognosis

Based in India, Dognosis provides AI-enabled disease detection solutions utilizing the olfactory abilities of dogs, aiming to revolutionize health monitoring and diagnostics. Based in Bengaluru, India, founded in 2023. Dognosis specializes in advanced disease detection solutions that harness the unique sense of smell of dogs alongside artificial intelligence technologies. The Company was co-founded by Akash Kulgod and Itamar Bitan.

In March 2026, Dognosis raised venture funding from Accel and Prosus Ventures, marking a significant step in its growth strategy. Dognosis specializes in advanced disease detection solutions that leverage the unique olfactory capabilities of dogs combined with cutting-edge artificial intelligence technologies. Their flagship product, BreathEasy, is a non-invasive health monitoring tool that analyzes volatile organic compounds (VOCs) in breath samples to generate a risk score for various diseases, including cancer. Patients use a specially designed mask to provide breath samples, which are then sent to Dognosis labs for analysis using their proprietary DogSense brain-computer interface (BCI) and DogOS machine learning models.

This innovative approach allows for high-accuracy disease detection and is currently being validated in large-scale trials. Dognosis targets healthcare providers, researchers, and clinicians across multiple geographic markets, including North America and Asia, aiming to fulfill the growing demand for effective cancer screening solutions. Dognosis generates revenue through its proprietary services, primarily the BreathEasy health monitoring tool, which is positioned as a B2B offering for healthcare providers and clinical settings. The transactional structure typically involves contracts with healthcare institutions that utilize Dognosis's technology for early disease detection and monitoring.

Clients pay for each batch of analyzed breath samples, which are processed in controlled laboratory environments. This pricing model allows for scalability as more healthcare entities recognize the efficacy of canine olfaction technology in disease detection. Collaborations and partnerships with medical institutions further enhance revenue opportunities, positioning Dognosis to capitalize on the increasing need for innovative diagnostic solutions in the medical field. The company plans to use the March 2026 funding to develop a non-invasive cancer detection platform combining biological sensing, robotics, and artificial intelligence.